Kura Oncology Inc (NAS:KURA)
$ 11.04 -0.13 (-1.16%) Market Cap: 858.51 Mil Enterprise Value: 419.84 Mil PE Ratio: 0 PB Ratio: 2.03 GF Score: 42/100

Kura Oncology Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 09:20PM GMT
Release Date Price: $16.07 (+1.39%)
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research

My name is Ying Huang. I'm the senior biotech analyst here at Bank of America Merrill Lynch. And welcome to the first day of BofA Merrill Healthcare Conference. And I'm very pleased to announce the next presenting company, Kura Oncology. We have Troy Wilson. Dr. Wilson is the President and CEO of Kura. With that, let me welcome Dr. Troy.

Troy Edward Wilson
Kura Oncology, Inc. - Chairman, CEO & President

Good afternoon, everyone. Thank you, Ying, for the introduction, and thanks to Bank of America Merrill Lynch for the invitation to present. As mentioned, I'm Troy Wilson, the President and CEO Kura Oncology. I'll be making certain forward-looking statements, and I refer you to the SEC's website or our website for additional information on the company.

Kura is a precision medicine company advancing a pipeline of targeted therapeutics. We have multiple assets in our portfolio, including 3 programs shown here from left to right: tipifarnib; which is our farnesyl

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot